Copyright
©The Author(s) 2019.
World J Clin Oncol. Jun 24, 2019; 10(6): 222-233
Published online Jun 24, 2019. doi: 10.5306/wjco.v10.i6.222
Published online Jun 24, 2019. doi: 10.5306/wjco.v10.i6.222
Figure 6 Leptin increases survival of endometrial cancer cells treated with paclitaxel.
A, B: Dose-response effects of paclitaxel (PTX) on survival of Ishikawa (A) and An3Ca cells (B) cultured with leptin (0 and 1.2nM) and leptin signaling inhibitor (IONP-LPrA2; 0.0036pM) for 3 d. The relative number of live cells (Survival% compared to basal) was calculated using Annexin V/FITC/PI assay by image cytometry using a Cellometer Vision CBA system (Nexcelom Biosciences, Lawrence, MA) and CCK8 assay (Cell counting kit-8 (Dojindo Molecular Technologies, Inc., Japan). The red line indicates the PTX EC50 calculated for each cell line. Arrows indicate PTX concentrations required to reduce 50% cell viability. Note that EC50 for PTX increases when leptin was added but was reduced when IONP-LPrA2 was added. Data (mean ± SE) are representative of the results derived from a minimum of three independent experiments.
- Citation: Daley-Brown D, Harbuzariu A, Kurian AA, Oprea-Ilies G, Gonzalez-Perez RR. Leptin-induced Notch and IL-1 signaling crosstalk in endometrial adenocarcinoma is associated with invasiveness and chemoresistance. World J Clin Oncol 2019; 10(6): 222-233
- URL: https://www.wjgnet.com/2218-4333/full/v10/i6/222.htm
- DOI: https://dx.doi.org/10.5306/wjco.v10.i6.222